MT 12

01/01/2022 - "In the BC xenograft mouse model, autophagy inhibitor 3-MA alleviated the inhibitory effect of MT-12 on tumor growth. "
02/01/2019 - "In the BC xenograft mouse model, the results revealed that MT-12 might decrease tumor growth and weight. "
01/01/2016 - "The mice treated with 2T-Dox-MNCs + multistage magnetic targeting (MT) (2 h d(-1) ) show 7.63-fold, 3.25-fold, and 2.7-fold reduction in HER2-positive tumor volume compared to Dox-MNCs, 2T-Dox-MNCs, and 2T-Dox-MNCs + single MT (12 h). "
02/01/2019 - "The results of the present study, suggest that MT-12 could effectively inhibit BC cell growth and metastasis via inhibition of tumor angiogenesis. "
02/01/2019 - "MT-12 inhibits the growth and metastasis of bladder cancer cells via suppressing tumor angiogenesis in vivo and in vitro."

01/01/2022 - "In this study, we explored whether MT-12 inhibits BC cell proliferation by inducing autophagy cell death through mitochondrial dysfunction. "
01/01/2022 - "MT-12 induces mitochondrial dysfunction and decreases autophagy, leading to increased ROS production, which in turn activates the JNK/p53 pathway, leading to BC apoptosis."
01/01/2022 - "MT-12 inhibits the proliferation of bladder cells in vitro and in vivo by enhancing autophagy through mitochondrial dysfunction."

02/01/2019 - "The results of the present study, suggest that MT-12 could effectively inhibit BC cell growth and metastasis via inhibition of tumor angiogenesis. "
02/01/2019 - "MT-12 inhibits the growth and metastasis of bladder cancer cells via suppressing tumor angiogenesis in vivo and in vitro."

01/01/2012 - "To conclude, MT-12 is capable of inhibiting the proliferation and invasion of bladder cancer EJ cells. "
01/01/2012 - "The results indicated that MT-12 inhibited the proliferation of bladder cancer cells in a dose-dependent manner. "
02/01/2019 - "MT-12 inhibits the growth and metastasis of bladder cancer cells via suppressing tumor angiogenesis in vivo and in vitro."

09/01/2004 - "MRI examinations of 23 patients affected by IP (16 primary and 7 recurrent) and 23 patients affected by malignant tumors (MT; 12 adenocarcinomas, 9 squamous cell carcinomas, and 2 neuroendocrine carcinomas) of the sinonasal tract were evaluated. "